Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.
What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.
In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.
Adjuvant osimertinib has been approved for the treatment of patients with resectable early-stage EGFR-positive NSCLC for 2 years. A lung cancer expert discusses the continued DFS benefit and lack of OS data to date and reviews considerations for using adjuvant osimertinib in the clinic.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.